Trade IMCR stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Immunocore Holdings plc American Depositary Shares (IMCR) is trading at US$32.00, down 0.93% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$1.9B. Over the past 52 weeks, IMCR has traded between US$27.56 and US$40.71. On Syfe you can trade IMCR with $0 commission and add it to your watchlist.
| Previous close | US$32.30 |
|---|---|
| Market cap | US$1.9B |
| 52-week range | US$27.56 – US$40.71 |
| Volume | 475.6K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Immunocore Holdings plc American Depositary Shares
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. the firm's lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
Year: 2021
--Earnings Flash (IMCR) Immunocore Posts Q2 Loss $0.02 a Share, vs. FactSet Est of $0.02 Loss
Aug 6, 11:22 AM · MT Newswires
-- Earnings Flash (IMCR) Immunocore Holdings plc Reports Q2 Revenue $115.9M, vs. FactSet Est of $110.4M
Aug 6, 11:14 AM · MT Newswires
Immunocore Reports 14.3-Month Survival in Phase 1/2 Trial of Advanced Melanoma Drug Candidate
Jun 1, 9:20 AM · MT Newswires
Mizuho Cuts Price Target on Immunocore Holdings to $34 From $38, Keeps Neutral Rating
May 8, 1:13 PM · MT Newswires
Stay on top of IMCR
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
